The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
Open accessAbstract
BACKGROUND: Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay). METHODS: Circulating tumour cells were enumerated in 60 patients with metastatic carcinomas of breast, prostate and lung origins using CellSearch according to the manufacturer's protocol and ISET by studying cytomorphology and immunolabelling with anti-cytokeratin or lineage-specific antibodies. RESULTS: Concordant results were obtained in 55% (11 out of 20) of the patients with breast cancer, in 60% (12 out of 20) of the patients with prostate cancer and in only 20% (4 out of 20) of lung cancer patients. CONCLUSION: Our results highlight important discrepancies between the numbers of CTC enumerated by both techniques. These differences depend mostly on the tumour type. These results suggest that technologies limiting CTC capture to EpCAM-positive cells, may present important limitations, especially in patients with metastatic lung carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 12×
“However, the specificity of CellSearch has been reliably documented in normal individuals and in patients with benign tumours (Allard et al, 2004).”
BackgroundInfluentialde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,841
Isolation by Size of Epithelial Tumor Cells
Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schütze, K., Capron, F., Franco, D., Pazzagli, M., Vekemans, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64706-2 · Cited by 1,069
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
Circulating tumor cells (CTC) detection: Clinical impact and future directions
Paterlini-Brechot, P., & Benali, N. L. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.014 · Cited by 947
Cited by
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
Haber, D. A., & Velculescu, V. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1014 · Cited by 694
Circulating tumor cell technologies
Ferreira, M. M., Ramani, V. C., & Jeffrey, S. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.007 · Cited by 511
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Marrugo-Ramírez, J., Mir, M., & Samitier, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102877 · Cited by 437
Stability of the hybrid epithelial/mesenchymal phenotype
Jolly, M. K., Tripathi, S. C., Jia, D., Mooney, S. M., Celiktas, M., Hanash, S. M., Mani, S. A., Pienta, K. J., Ben-Jacob, E., & Levine, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8166 · Cited by 436
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
L�cke, K. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1557 · Cited by 314
Pailler, E., Adam, J., Barthélémy, A., Oulhen, M., Auger, N., Valent, A., Borget, I., Planchard, D., Taylor, M., André, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5932 · Cited by 284
Self-citationA pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.545 · Cited by 255
Metadata
- Authors
- Farace, F., Massard, C., Vimond, N., Drusch, F., Jacques, N., Billiot, F., Laplanche, A., Chauchereau, A., Lacroix, L., Planchard, D., Le Moulec, S., André, F., Fizazi, K., Soria, J. C., & Vielh, P.
- Venue
- British Journal of Cancer
- Published
- 2011-08-09
- Volume
- 105
- Issue
- 6
- Pages
- 847-853
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1965491427
- Cited by
- 407
- References
- 23
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.